Abstract
Abstract
RE-MIND2 (NCT04697160) compared patient outcomes from the L-MIND (NCT02399085) trial of tafasitamab+lenalidomide with those of patients treated with other therapies for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are autologous stem cell transplant ineligible. We present outcomes data for three pre-specified treatments not assessed in the primary analysis.
Data were retrospectively collected from sites in North America, Europe, and the Asia Pacific region. Patients were aged ≥18 years with histologically confirmed DLBCL and received ≥2 systemic therapies for DLBCL (including ≥1 anti-CD20 therapy). Patients enrolled in the observational and L-MIND cohorts were matched using propensity score-based 1:1 nearest-neighbor matching, balanced for six covariates. Tafasitamab+lenalidomide was compared with polatuzumab vedotin+bendamustine+rituximab (pola-BR), rituximab+lenalidomide (R2), and CD19-chimeric antigen receptor T-cell (CAR-T) therapies. The primary endpoint was overall survival (OS). Secondary endpoints included treatment response and progression-free survival.
From 200 sites, 3,454 patients were enrolled in the observational cohort. Strictly matched patient pairs consisted of tafasitamab+lenalidomide versus pola-BR (n = 24 pairs), versus R2 (n = 33 pairs), and versus CAR-T therapies (n = 37 pairs). A significant OS benefit was observed with tafasitamab+lenalidomide versus pola-BR (HR: 0.441; p = 0.034) and R2 (HR: 0.435; p = 0.012). Comparable OS was observed in tafasitamab+lenalidomide and CAR-T cohorts (HR: 0.953, p = 0.892).
Tafasitamab+lenalidomide appeared to improve survival outcomes versus pola-BR and R2, and comparable outcomes were observed versus CAR-T. Although based on limited patient numbers, these data may help to contextualize emerging therapies for R/R DLBCL.
Clinical trial registration
NCT04697160 (January 6, 2021)
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference46 articles.
1. Salles G, Duell J, González Barca E et al (2020) Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 21:978–988. https://doi.org/10.1016/S1470-2045(20)30225-4
2. Duell J, Maddocks KJ, González-Barca E et al (2021) Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 106:2417–2426. https://doi.org/10.3324/haematol.2020.275958
3. US Food & Drug Administration (2020) FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma. Accessed 23 Nov 2021
4. European Medicines Agency (2021) Tafasitamab Summary of Opinion: Committee for Medicinal Products for Human Use (CHMP). https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-minjuvi_en.pdf. Accessed 27 Jul 2021
5. Government of Canada, Health Canada, Public Affairs C and RB (2021) Drug Product Database: Minjuivi. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=100793. Accessed 21 Sep 2021
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献